DCGI Proposes Requiring Drug Maker Post-Marketing Monitoring Units
This article was originally published in PharmAsia News
Executive Summary
The Drug Controller General of India has proposed requiring drug makers to set up patient-monitoring units to track post-marketing adverse effects and the responses of developed nations in handling problems with a drug.